Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Zentalis Pharmaceuticals (ZNTL) over the last 2 years, with Q1 2025 value amounting to $1.2 million.

  • Zentalis Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $1.2 million in Q1 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 235106.38%. This contributed to the annual value of $5.0 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Zentalis Pharmaceuticals' Asset Writedowns and Impairment is $1.2 million.
  • In the past 5 years, Zentalis Pharmaceuticals' Asset Writedowns and Impairment ranged from a high of $5.0 million in Q1 2023 and a low of $47000.0 during Q4 2023